This company has been marked as potentially delisted and may not be actively trading. Oaktree Acquisition (OAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OAC vs. CRSP, AXSM, LEGN, NUVL, IRTC, RDNT, PCVX, MTSR, KRYS, and TGTXShould you be buying Oaktree Acquisition stock or one of its competitors? The main competitors of Oaktree Acquisition include CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), Nuvalent (NUVL), iRhythm Technologies (IRTC), RadNet (RDNT), Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), and TG Therapeutics (TGTX). These companies are all part of the "medical" sector. Oaktree Acquisition vs. Its Competitors CRISPR Therapeutics Axsome Therapeutics Legend Biotech Nuvalent iRhythm Technologies RadNet Vaxcyte Metsera Krystal Biotech TG Therapeutics CRISPR Therapeutics (NASDAQ:CRSP) and Oaktree Acquisition (NYSE:OAC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Does the media prefer CRSP or OAC? In the previous week, CRISPR Therapeutics had 31 more articles in the media than Oaktree Acquisition. MarketBeat recorded 32 mentions for CRISPR Therapeutics and 1 mentions for Oaktree Acquisition. CRISPR Therapeutics' average media sentiment score of 0.72 beat Oaktree Acquisition's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 16 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oaktree Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CRSP or OAC more profitable? Oaktree Acquisition has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,229.43%. Oaktree Acquisition's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Oaktree Acquisition N/A N/A N/A Which has more volatility & risk, CRSP or OAC? CRISPR Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Oaktree Acquisition has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Do institutionals & insiders believe in CRSP or OAC? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Oaktree Acquisition shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable valuation & earnings, CRSP or OAC? Oaktree Acquisition has lower revenue, but higher earnings than CRISPR Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M180.32-$366.25M-$5.43-13.62Oaktree AcquisitionN/AN/A$1.15MN/AN/A Do analysts prefer CRSP or OAC? CRISPR Therapeutics presently has a consensus price target of $72.59, indicating a potential downside of 1.87%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe CRISPR Therapeutics is more favorable than Oaktree Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 2 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.42Oaktree Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCRISPR Therapeutics beats Oaktree Acquisition on 9 of the 13 factors compared between the two stocks. Get Oaktree Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for OAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OAC vs. The Competition Export to ExcelMetricOaktree AcquisitionOffices & Clinics Of Medical Doctors IndustryMedical SectorNYSE ExchangeMarket Cap$1.29B$33.61M$6.13B$21.84BDividend YieldN/AN/A5.72%3.62%P/E RatioN/AN/A29.4832.72Price / SalesN/A0.60501.5165.72Price / Cash377.4554.0325.8218.06Price / Book256.800.3912.544.71Net Income$1.15M-$7.06M$3.32B$1.02B Oaktree Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OACOaktree AcquisitionN/A$51.36+3.2%N/A+124.7%$1.29BN/A0.00N/AGap UpHigh Trading VolumeCRSPCRISPR Therapeutics1.9405 of 5 stars$71.82+3.5%$71.71-0.2%+51.2%$6.31B$35M-13.23460Insider TradeGap UpAXSMAxsome Therapeutics4.7769 of 5 stars$129.58+4.9%$177.93+37.3%+41.0%$6.16B$385.69M-25.56380Positive NewsAnalyst ForecastLEGNLegend Biotech2.9344 of 5 stars$33.72+1.5%$69.25+105.4%-23.2%$6.13B$627.24M-38.322,609NUVLNuvalent2.5587 of 5 stars$89.64+5.9%$120.50+34.4%-5.5%$6.10BN/A-18.2940Analyst RevisionIRTCiRhythm Technologies1.5316 of 5 stars$175.67-0.7%$184.85+5.2%+190.8%$5.68B$657.23M-59.962,000RDNTRadNet3.2807 of 5 stars$76.78+4.0%$76.80+0.0%+15.1%$5.68B$1.83B-383.8811,021News CoveragePositive NewsGap UpPCVXVaxcyte2.3524 of 5 stars$43.94+2.5%$106.25+141.8%-62.9%$5.56BN/A-10.69160Gap UpMTSRMetseraN/A$52.78+0.5%$55.75+5.6%N/A$5.52BN/A0.0081KRYSKrystal Biotech4.7135 of 5 stars$192.99+2.6%$209.00+8.3%+9.4%$5.44B$290.52M39.23210News CoverageTGTXTG Therapeutics4.0912 of 5 stars$35.05+2.7%$49.00+39.8%+50.7%$5.42B$454.07M94.73290 Related Companies and Tools Related Companies CRISPR Therapeutics Competitors Axsome Therapeutics Competitors Legend Biotech Competitors Nuvalent Competitors iRhythm Technologies Competitors RadNet Competitors Vaxcyte Competitors Metsera Competitors Krystal Biotech Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OAC) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oaktree Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oaktree Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OAC Stock Alerts